Risk of Nocturnal Hypoglycemia & Arrhythmias With Sitagliptin Versus

Status Terminated

Clinical Trial Summary

This exploratory double blind randomized active controlled study is designed to assess the effects of a treatment with therapeutical dosage of sitagliptin versus therapeutical dosage of glimepiride as add on therapy in patients with diabetes mellitus type 2 (T2DM) patients inadequately controlled on metformin monotherapy.

Clinical Trial Description

Type 2 Diabetes is associated with an increased cardiovascular morbidity and mortality. Among patients insufficiently controlled with metformin multimorbidity and polypharmacy is common that makes the patients frail for cardiovascular complications related to hypoglycemic events.

This exploratory double blind randomized active controlled study is designed to assess the effects of a treatment with therapeutical dosage of sitagliptin versus therapeutical dosage of glimepiride as add on therapy in patients with T2DM patients inadequately controlled on metformin monotherapy.

Examinations will be performed as a 5 day recording of subcutaneous glucose concentration (CGMS) and holder ECG (AMEDTEC) at baseline and after a 12 weeks treatment with sitagliptin or glimepiride as active comparators used in combination with metformin.

With recording of nocturnal hypoglycemia and arrhythmias it is aimed to evaluate favorable glycemic profile under treatment with sitagliptin compared to glimepiride. The primary objective is risk of serious HE for both drugs.

The glycemic profile of sitagliptin as add-on therapy to metformin seems to be favorable compared to sulfonylureass such as glimepiride. Treatment with sitagliptin as add-on to metformin therapy causes less glycemic fluctuations and may be associated with lower oxidative stress and down regulation of low grade inflammation. This hypothesis will be tested as an explorative double blind study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02373865
Study type	Interventional
Source	GWT-TUD GmbH
Contact
Status	Terminated
Phase	Phase 4
Start date	September 2015
Completion date	January 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01267448` - Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia	Phase 4
Active, not recruiting	`NCT05330247` - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study	N/A
Terminated	`NCT02743598` - Liraglutide for HIV-associated Neurocognitive Disorder	Phase 4
Completed	`NCT01741181` - Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2	Phase 4
Completed	`NCT01305434` - Mulberry Leaf Extract and Blood Glucose Control in Diabetics	Phase 1/Phase 2
Completed	`NCT01330121` - Bridging the Gap by Transitional Care	N/A
Recruiting	`NCT00992797` - Diabetes Intervention Trial With Vitamin D in Subjects of Nordic and Sub-Indian Ethnicity	Phase 2
Completed	`NCT01580904` - Impact of Pharmaceutical Care in Diabetics Patients	N/A
Active, not recruiting	`NCT00728403` - Metabolic and Therapeutic Effects of American and Korean Red Ginseng in the Treatment of Type 2 Diabetes	Phase 2
Completed	`NCT00763815` - GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone	Phase 3
Active, not recruiting	`NCT00529815` - Continuous Glucose Monitoring in Patients With Type 2 Diabetes	Phase 4
Completed	`NCT00517465` - A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.	Phase 1
Withdrawn	`NCT00417716` - Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema	Phase 3
Completed	`NCT00119041` - Diabetes Telemedicine Consultation: A Systems Improvement Intervention	N/A
Withdrawn	`NCT00600236` - HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population	Phase 3
Active, not recruiting	`NCT05887635` - Study of Duodenal Mucosal RF Vapor Ablation in Subjects With Type-2 Diabetes Mellitus	N/A
Completed	`NCT03903965` - Comparison of Retinal Perfusion Between Diabetic and Non-diabetic Patients With OCT Angiography After Cataract Surgery.
Completed	`NCT02666924` - Cooking Classes for Chinese Canadian Patients Living With Diabetes	N/A
Recruiting	`NCT02501850` - The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)	Phase 4
Completed	`NCT01964833` - PDT and Periodontal Treatment in DMT2 Patients	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms